IMA vs PATH
ImageneBio, Inc. (IMA) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
ImageneBio, Inc. (IMA) is a biotechnology company listed on NASDAQ.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported IMA revenue for 2023-12-31 was $9.2M. Net income was -$68.2M. Revenue was down 41.3% from 2022-12-31 to 2023-12-31. IMA currently screens at market cap $64.7M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
IMA currently screens at market cap $64.7M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the IMA and PATH stock pages for the full models.
Not investment advice.